BRAF V600E、p53、CD56、CK19、Galectin-3、TPO在247例甲状腺乳头状癌的表达与诊断价值
Expression of BRAF V600E, p53, CD56, CK19, Galectin-3, TPO in 247 Cases of Papillary Thyroid Carcinoma and Its Diagnostic Value
DOI: 10.12677/ACM.2022.1281044, PDF,   
作者: 胡诗梦, 王 敏*：湖南师范大学附属第一医院内分泌科，湖南 长沙
关键词: 甲状腺乳头状癌；BRAF V600E；p53；CD56；CK19；Galectin-3；TPO；诊断价值；Papillary Thyroid Carcinoma； BRAF V600E； p53； CD56； CK19； Galectin-3； TPO； Diagnostic Value
摘要: 目的：探讨甲状腺乳头状癌(papillary thyroid carcinoma, PTC)的BRAF V600E、p53、CD56、CK19、Galectin-3、TPO的表达及诊断价值。方法：选取2019年12月至2021年12月在我院行手术治疗的PTC患者共247例为研究对象，收集其BRAF V600E、p53、CD56、CK19、Galectin-3、TPO表达情况，做出对比分析。结果：在247例PTC中，BRAF V600E、p53异常突变、CD56、CK19、Galectin-3、TPO的阳性率分别为95.95%、47.37%、22.27%、98.38%、99.19%、28.74%。结论：BRAF V600E、p53、CD56、CK19、Galectin-3、TPO检测对甲状腺乳头状癌的诊断意义重大。
Abstract: Objective: To investigate the expression and diagnostic value of BRAF V600E, p53, CD56, CK19, Ga-lectin-3 and TPO in papillary thyroid carcinoma. Methods: A total of 247 patients with papillary thyroid carcinoma who underwent surgery in our hospital from December 2019 to December 2021 were selected as the research objects. The expression of BRAF V600E, p53, CD56, CK19, Galectin-3 and TPO were collected and compared to draw a conclusion. Results: In 247 cases of PTC, the posi-tive rates of BRAF V600E, p53, CD56, CK19, Galectin-3 and TPO were 95.95%, 47.37%, 22.27%, 98.38%, 99.19% and 28.74% respectively. Conclusion: The detection of BRAF V600E, p53, CD56, CK19, Galectin-3 and TPO is of great significance in the diagnosis of papillary thyroid carcinoma.
文章引用：胡诗梦, 王敏. BRAF V600E、p53、CD56、CK19、Galectin-3、TPO在247例甲状腺乳头状癌的表达与诊断价值[J]. 临床医学进展, 2022, 12(8): 7233-7237. https://doi.org/10.12677/ACM.2022.1281044

参考文献

[1] Silva, S.N. (2021) Special Issue: Genetic Perspectives in Thyroid Cancer. Genes (Basel), 12, 126. [Google Scholar] [CrossRef] [PubMed]
[2] Du, L., Li, R., Ge, M., et al. (2019) Incidence and Mortality of Thy-roid Cancer in China, 2008-2012. Chinese Journal of Cancer Research, 31, 144-151. [Google Scholar] [CrossRef] [PubMed]
[3] Du, L., Zhao, Z., Zheng, R., et al. (2020) Epidemiology of Thyroid Cancer: Incidence and Mortality in China, 2015. Frontiers in Oncology, 10, Article No. 1702. [Google Scholar] [CrossRef] [PubMed]
[4] 卢平, 胡婕, 程双华, 等. 甲状腺乳头状癌患者TPO与CD56表达的诊断价值[J]. 诊断病理学杂志, 2020, 27(3): 172-175.
[5] Cibas, E.S. and Ali, S.Z. (2017) The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid, 27, 1341-1346. [Google Scholar] [CrossRef] [PubMed]
[6] Kimura, E.T., Nikiforova, M.N., Zhu, Z., et al. (2003) High Prevalence of BRAF Mutations in Thyroid Cancer: Genetic Evidence for Constitutive Activation of the RET/PTC-RAS-BRAF Sig-naling Pathway in Papillary Thyroid Carcinoma. Cancer Research, 63, 1454-1457.
[7] Perdas, E., Stawski, R., Nowak, D., et al. (2018) Potential of Liquid Biopsy in Papillary Thyroid Carcinoma in Context of miRNA, BRAF and p53 Muta-tion. Current Drug Targets, 19, 1721-1729. [Google Scholar] [CrossRef] [PubMed]
[8] 侯卫华, 李从洋, 孟祥超, 刘艳锋, 于兵兵, 张萌, 王建业, 段尚林, 胡学信. 免疫组化蛋白标志物在甲状腺乳头状癌组织中的表达[J]. 肿瘤基础与临床, 2018, 31(3): 192-195.
[9] Huang, L., Wang, X., Huang, X., et al. (2018) Diagnostic Significance of CK19, Galectin-3, CD56, TPO and Ki67 Expression and BRAF Mutation in Papillary Thyroid Carcinoma. Oncology Letters, 5, 4269-4277. [Google Scholar] [CrossRef] [PubMed]
[10] Tastekin, E., Keskin, E., Can, N., et al. (2019) CD56, CD57, HBME1, CK19, Galectin-3 and p63 Immunohistochemical Stains in Differentiating Diagnosis of Thyroid Benign/Malign Lesions and NIFTP. Polish Journal of Pathology, 70, 286-294. [Google Scholar] [CrossRef] [PubMed]
[11] 王力群, 郑曦, 吴钦穗, 等. BRAF基因在甲状腺癌细针穿刺标本中的表达研究[J]. 中国医药指南, 2018, 16(19): 164-165.
[12] Basolo, F., Torregrossa, L., Giannini, R., et al. (2010) Correlation between the BRAF V600E Mutation and Tumor Invasiveness in Papillary Thyroid Carcinomas Smaller than 20 Millimeters: Analysis of 1060 Cases. The Journal of Clinical Endocrinology & Metabolism, 95, 4197-4205. [Google Scholar] [CrossRef] [PubMed]
[13] Kim, S.K., Woo, J.W., Lee, J.H., et al. (2016) Chronic Lymphocytic Thyroiditis and BRAF V600E in Papillary Thyroid Car-cinoma. Endocrine-Related Cancer, 23, 27-34. [Google Scholar] [CrossRef] 
[14] Yan, C., Huang, M., Li, X., et al. (2019) Relationship between BRAF V600E and Clinical Features in Papillary Thyroid Carcinoma. Endocrine Connections, 8, 988-996. [Google Scholar] [CrossRef] 
[15] 赵慧敏. 甲状腺癌的分子诊断现状研究[J]. 检验医学与临床, 2020, 17(8): 1135-1138.
[16] Ceyran, A.B., Senol, S., Simsek, B.Ç., et al. (2015) Role of CD56 and e-Cadherin Expression in the Differential Diagnosis of Papillary Thyroid Carcinoma and Suspected Follicular-Patterned Lesions of the Thyroid: The Prognostic Importance of e-Cadherin. International Journal of Clinical and Experimental Pathology, 8, 3670-3680.
[17] 冯耀霞, 张岚, 李群锋, 等. 恶性潜能未定的高分化甲状腺肿瘤中CK19、Galectin-3、HBME-1和TPO的表达及意义[J]. 实用肿瘤杂志, 2017, 32(4): 362-366.
[18] 许军, 丁旭贝, 肖光雄. 甲状腺微小乳头状癌组织中CK19、TPO、Galectin-3和Survivin蛋白表达水平及诊断价值[J]. 解放军医药杂志, 2017, 29(6): 48-50.
[19] Liu, Z., Li, X., Shi, L., et al. (2014) Cytokeratin 19, Thyroperoxidase, HBME-1 and Galectin-3 in Evalua-tion of Aggressive Behavior of Papillary Thyroid Carcinoma. International Journal of Clinical and Experimental Medi-cine, 7, 2304-2308.
[20] 周荣璟, 丁金旺, 赵海菲, 等. 甲状腺良恶性病变中HCK、HBME-1及TPO的表达及临床价值[J]. 浙江医学, 2017, 39(22): 1972-1975.

为你推荐